$QGEN (Qiagen NV)

$QGEN {{ '2016-09-12T09:17:25+0000' | timeago}} • Announcement

$QGEN said no meaningful revenue contribution from GeneReader NGS System were included in its 2016 financial forecasts. Company also does not expect a material impact from the court's decision on its full-year 2016 outlook nor anticipates any material changes to its internal 2017 projections. A trial date in the case is scheduled for Nov. 2017.

$ABBV {{ '2017-07-21T16:09:32+0000' | timeago}} • Announcement

$ABBV received positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency for Humira (adalimumab) for the treatment of chronic non-infectious anterior uveitis in pediatric patients. Uveitis is an inflammation of the uvea, which includes the iris, choroid, and the ciliary body in eye.

$MCK {{ '2017-07-21T16:07:44+0000' | timeago}} • Announcement

Biologics, a unit of healthcare technology firm $MCK, said it will join the limited distribution network of $PBYI to promote the latter’s kinase inhibitor Nerlynx. The formulation is indicated for treatment of adult patients with early-stage HER2 overexpressed/amplified breast cancer.

$REGN {{ '2017-07-21T15:50:38+0000' | timeago}} • Announcement

$REGN and $SNY announced that the European Medicine Agency's Committee for Medicinal Products for Human Use has given a positive opinion for the marketing authorization of Dupixent (dupilumab), recommending its approval in Europe for use in adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.

$ENDP {{ '2017-07-21T14:56:21+0000' | timeago}} • Announcement

$ENDP said it will be ceasing operations and closing its manufacturing and distribution facilities in Huntsville, Alabama. The closure is expected to take place over the next 12 to 18 months. These restructuring actions are expected to reduce $ENDP's workforce by about 875 positions and to result in pre-tax restructuring charges of about $325MM.

$GE {{ '2017-07-21T12:51:53+0000' | timeago}} • Infographic

$GE General Electric Earnings AlphaGraphics: Q2 2017 highlights

$ISRG {{ '2017-07-21T12:26:16+0000' | timeago}} • Infographic

$ISRG Intuitive Surgical, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$GE {{ '2017-07-21T11:43:55+0000' | timeago}} • Announcement

$GE CEO Jeff Immelt said, "We expect cash flow to continue to improve throughout the year. We’ve reduced our industrial structural costs year-to-date by $670MM and we are on track to meet or exceed our $1Bil cost reduction target for the year."

$GE {{ '2017-07-21T11:40:52+0000' | timeago}} • Announcement

Primarily due to $GE's shift of focus into industrial operations, its backlog in 2Q17 grew 2% to $327Bil, while orders increased 6% to $28.3Bil. $GE has a history of orders and backlogs growing faster than its revenue.

$GE {{ '2017-07-21T11:38:01+0000' | timeago}} • Announcement

$GE's total revenue in 2Q17 fell 12% to $29.6Bil due to weakness in its Energy Connections segment, which supplies automation products to various industries including marine, mining and oil & gas. Revenue from this segment fell 27% during the quarter.

$GE {{ '2017-07-21T11:35:13+0000' | timeago}} • Announcement

In 2Q17, which marks the end of Jeff Immelt at the helm of $GE after 16 years, the multinational conglomerate posted net earnings that more-than-halved to $1.19Bil, or $0.13 per share. On a non-GAAP basis, EPS declined 45% to $0.28 during the quarter.

$ISRG {{ '2017-07-20T20:21:13+0000' | timeago}} • Announcement

In 2Q17, $ISRG's service revenue rose 11% to $142MM while instrument and accessory revenue jumped 17% to $398MM. Intuitive Surgical ended the second quarter with $3.4Bil in cash, cash equivalents, and investments.

$ISRG {{ '2017-07-20T20:16:13+0000' | timeago}} • Announcement

In 2Q17, revenue for $ISRG jumped 13% to $756MM while net income soared 20% to $222MM or $5.77 per diluted share. Non-GAAP net income was $228MM or $5.95 per diluted share, with systems revenue increased by approximately 7% to $216MM.

$ABT {{ '2017-07-20T19:55:45+0000' | timeago}} • Webcast

For 3Q17, $ABT expects adjusted EPS of $0.64-0.66, with operational sales growth expected in the mid-single digits. At current exchange rates, the company expects operational sales growth to have a negative YoY impact of around 0.5%.

$ABT {{ '2017-07-20T19:45:56+0000' | timeago}} • Webcast

$ABT said that on a comparable operational basis, 3Q17 Established Pharmaceuticals sales growth is expected in the high double-digit, while in Nutrition, sales growth is expected in low single-digit. In Diagnostics, $ABT expects sales to increase mid-to-high single digits and in Medical Devices, sales is expected to increase double-digits.

$ABT {{ '2017-07-20T17:49:19+0000' | timeago}} • Announcement

$ABT raised its full year profit forecast backed by the intention of closing the Alere acquisition in 2017. The company raised its FY17 adjusted earnings from continuing operations guidance by $0.03 to a range of $2.43-2.53 per share. Reported EPS forecast was also raised from the range of $0.92-1.02 to $1.03-1.13, reflecting double-digit growth.

$ABT {{ '2017-07-20T17:36:53+0000' | timeago}} • Announcement

Declining operating earnings and rising costs and expenses hit $ABT 2Q17 earnings as much as 54%. Earnings plunged to $283MM or $0.15 from $615MM or $0.40 per share a year earlier. Sales, however, surged 24.4% on St. Jude Medical acquisition. On an adjusted basis, $ABT reported EPS above its previous guidance range at $0.62 per share.

$ABT {{ '2017-07-20T12:52:57+0000' | timeago}} • Infographic

$ABT Abbott Laboratories Earnings AlphaGraphic: Q2 2017 Highlights

$NEM {{ '2017-07-19T20:55:03+0000' | timeago}} • Announcement

$NEM elected Sheri Hickok and Molly Zhang to its BoD. Hickok is currently General Manager, Global Product Development, Onshore Wind at $GE's Renewable Energy. Zhang currently serves as a director of Cooper Standard Automotive and XG Science as a supervisory board member at GEA Group in Germany.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$TMO {{ '2017-07-19T12:44:47+0000' | timeago}} • Announcement

$TMO priced an offering of EUR2.6Bil of senior notes. The issuance of the notes is expected to close on or about July 24, 2017. $TMO plans to use all of net proceeds to fund a portion of consideration payable for its acquisition of Patheon, including the repayment of debt of Patheon to be assumed by $TMO, which is estimated to be about $7.2Bil.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, July 20 2017 - 8:30pm
ABT (Abbott Laboratories)
Thursday, July 20 2017 - 1:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
A (Agilent Technologies Inc.)
Monday, May 22 2017 - 8:30pm
MCK (McKesson Corporation)
Thursday, May 18 2017 - 9:00pm
PTX (Pernix Therapeutics Holdings, Inc.)
Monday, May 15 2017 - 8:30pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
HOLX (Hologic Inc.)
Wednesday, May 10 2017 - 8:30pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
BDX (Becton, Dickinson and Company)
Thursday, May 4 2017 - 12:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
MYGN (Myriad Genetics, Inc.)
Tuesday, May 2 2017 - 8:30pm
GNMK (GenMark Diagnostics, Inc.)
Tuesday, May 2 2017 - 8:30pm
TECH (Bio-Techne Corp.)
Tuesday, May 2 2017 - 1:00pm
BDX (Becton, Dickinson and Company)
Tuesday, May 2 2017 - 12:00pm
SGEN (Seattle Genetics, Inc.)
Thursday, April 27 2017 - 8:30pm
ABBV (AbbVie Inc.)
Thursday, April 27 2017 - 1:00pm
TMO (Thermo Fisher Scientific, Inc.)
Wednesday, April 26 2017 - 12:30pm
ILMN (Illumina Inc.)
Tuesday, April 25 2017 - 9:00pm

AlphaGraphics you may like